GSK Spends $10.6 Billion on Cancer Drug Bet After Consumer Health Spinoff

GSK acquired Boston biotech Nuvalent for $10.6 billion in cash on June 9, 2026. The deal reflects GSK's pivot since spinning off its consumer business, Haleon, in 2022: move toward specialty medicines and cancer treatments with stronger pricing power and fewer competitors. Nuvalent brings three lung cancer drugs to GSK's pipeline—a bet on future revenue rather than immediate profits.